Table 1 Relationship of lncMa-301 expression and overall survival with demographic and clinical data in HCC patients

Sex

 Female

13

16

0.79 (0.36–1.73)

0.549

29

Ref.

 Male

95

92

Ref.

187

2.00 (0.72–5.57)

Age, year

 < 60

84

90

0.70 (0.36–1.38)

0.302

174

Ref.

 ≥ 60

24

18

Ref.

42

0.53 (0.23–1.24)

Size, cm

 < 5

29

35

0.77 (0.43–1.38)

0.371

64

Ref.

 ≥ 5

79

73

Ref.

152

2.67 (1.20–5.95)

Number of tumors

 < 3

97

99

0.80 (0.32–20.2)

0.639

196

Ref.

 ≥ 3

11

9

Ref.

20

2.42 (1.13–5.17)

Tumor capsule

 Complete

59

65

0.80 (0.46–1.37)

0.409

124

Ref.

 Incomplete/absent

49

43

Ref.

92

2.03 (1.15–3.58)

Lymph node metastasis

 No

99

104

0.42 (0.13–1.42)

0.153

203

Ref.

 Yes

9

4

Ref.

13

3.06 (1.37–6.81)

Macrovascular invasion

 No

66

69

0.89 (0.51–1.54)

0.673

135

Ref.

 Yes

42

39

Ref.

81

2.92 (1.65–5.16)

Microvascular invasion

 No

42

45

0.89 (0.52–1.54)

0.677

87

Ref.

 Yes

66

63

Ref.

129

4.04 (1.89–8.62)

AFP, ng/mL

 < 400

53

55

0.93 (0.55–1.58)

0.785

108

Ref.

 ≥ 400

55

53

Ref.

108

1.47 (0.84–2.59)

BCLC stage

 0/A

47

51

0.86 (0.50–1.47)

0.585

98

Ref.

 B/C

61

57

Ref.

118

2.94 (1.53–5.65)

EST031.1 expression

 Low

108

0

NA

108

Ref.

 High

0

108

108

0.54 (0.30–0.96)